Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
| dc.rights.license | open | en_US |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | BROCHET, Bruno | |
| hal.structure.identifier | Fondazione IRCCS Istituto Neurologico "Carlo Besta" | |
| dc.contributor.author | SOLARI, Alessandra | |
| hal.structure.identifier | University of Newcastle [Callaghan, Australia] [UoN] | |
| dc.contributor.author | LECHNER-SCOTT, Jeannette | |
| hal.structure.identifier | Karolinska Institutet [Stockholm] | |
| dc.contributor.author | PIEHL, Fredrik | |
| hal.structure.identifier | Royal Holloway [University of London] [RHUL] | |
| dc.contributor.author | LANGDON, Dawn | |
| hal.structure.identifier | Maastricht University Medical Centre [MUMC] | |
| dc.contributor.author | HUPPERTS, Raymond | |
| hal.structure.identifier | University of Lódź = Uniwersytet Łódzki | |
| dc.contributor.author | SELMAJ, Krzysztof | |
| hal.structure.identifier | Università degli studi di Catania = University of Catania [Unict] | |
| dc.contributor.author | PATTI, Francesco | |
| hal.structure.identifier | University of Lleida-IRBLLEIDA-PCiTA | |
| dc.contributor.author | BRIEVA, Luis | |
| dc.contributor.author | MAIDA, Eva Maria | |
| hal.structure.identifier | Merck KGaA [Darmstadt, Germany] | |
| dc.contributor.author | ALEXANDRI, Nektaria | |
| hal.structure.identifier | Merck KGaA [Darmstadt, Germany] | |
| dc.contributor.author | SMYK, Andrzej | |
| hal.structure.identifier | Merck KGaA [Darmstadt, Germany] | |
| dc.contributor.author | NOLTING, Axel | |
| hal.structure.identifier | Merck KGaA [Darmstadt, Germany] | |
| dc.contributor.author | KELLER, Birgit | |
| hal.structure.identifier | Centre d'Esclerosi Múltiple de Catalunya [CemCat] | |
| dc.contributor.author | MONTALBAN, Xavier | |
| hal.structure.identifier | 1. lékařská fakulta, Univerzita Karlova [Praha, Česká republika] = First Faculty of Medicine, Charles University [Prague, Czech Republic] [1. LF UK / 1st Faculty of Medicine] | |
| dc.contributor.author | KUBALA HAVRDOVA, Eva | |
| dc.date.accessioned | 2024-04-26T11:42:09Z | |
| dc.date.available | 2024-04-26T11:42:09Z | |
| dc.date.issued | 2023-12 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/199355 | |
| dc.description.abstractEn | Background: Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL). Objective: To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) in CLARIFY-MS. Methods: Changes in the MS quality of life (MSQoL)-54 scores were analysed using a repeated mixed-effects linear model. Subgroup analyses were performed for participants who were pretreatment-naïve and those pretreated with disease-modifying therapies (DMTs) before initiating CladT. Safety and tolerability of CladT were also assessed. Results: MSQoL-54 physical (mean change = 4.86; 95% confidence interval (CI) = 3.18, 6.53) and mental health (4.80; 95% CI = 3.13, 6.46) composite scores (primary endpoints) showed significant improvement at Month 24 versus Baseline (p < 0.0001). Changes in the MSQoL-54 scores were consistent across the pretreatment-naïve and DMT-pretreated subgroups. No new severe or opportunistic infections occurred. Most post-baseline lymphopenia events were Grade 1–2 in severity. Transient Grade-3 lymphopenia was observed in 19.7% (95/482) of participants. Grade-4 lymphopenia was not observed. Conclusions: CladT treatment significantly improved the mean MSQoL-54 physical and mental health composite scores over 2 years. CladT efficacy in HRQoL, relapse rates and Expanded Disability Status Scale scores demonstrates its multidimensional effects in MS treatment. © The Author(s), 2023. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject.en | Cladribine tablets | |
| dc.subject.en | CLARIFY-MS | |
| dc.subject.en | Quality of life | |
| dc.subject.en | Disease-modifying therapies | |
| dc.subject.en | Multiple Sclerosis | |
| dc.title.en | Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study | |
| dc.title.alternative | Mult Scler | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1177/13524585231205962 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
| dc.identifier.pubmed | 37978852 | en_US |
| bordeaux.journal | Multiple Sclerosis Journal | en_US |
| bordeaux.page | 1808-1818 | en_US |
| bordeaux.volume | 29 | en_US |
| bordeaux.hal.laboratories | Neurocentre Magendie - U1215 | en_US |
| bordeaux.issue | 14 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | Relations glie-neurone | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Merck KGaA | en_US |
| hal.identifier | hal-04560552 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-04-26T11:42:11Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | CC BY-NC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Multiple%20Sclerosis%20Journal&rft.date=2023-12&rft.volume=29&rft.issue=14&rft.spage=1808-1818&rft.epage=1808-1818&rft.au=BROCHET,%20Bruno&SOLARI,%20Alessandra&LECHNER-SCOTT,%20Jeannette&PIEHL,%20Fredrik&LANGDON,%20Dawn&rft.genre=article |
